The global human microbiome market size is expected to reach USD 1,276.3 million by 2030, according to a new study by Polaris Market Research. The report “Human Microbiome Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, Supplements, and Others); By Application; By Disease, By Type; By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
With so many small high-tech firms functioning in the industry, there are numerous high-growth prospects for important stakeholders to purchase out corporations in order to investigate microbiomes with the goal of uncovering novel medications and therapeutic targets for various indications such as obesity, diabetes, liver problems, and metabolic diseases. Many industry leaders are working on strategic alliances and partnerships to expand their product pipelines through well-organized R&D approaches.
Several alliances and partnerships involving large corporations have occurred in the recent two years. The FDA has not authorized any probiotics as a live biotechnology-derived product. However, there are U.S. food and drug administration foods, including nutritional supplements, incorporating microorganisms that are legitimately accessible. Still, these items cannot be legally advertised to reduce or avoid illness.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/human-microbiome-market/request-for-sample
The federal government’s increased investment is expected to support market expansion. Furthermore, the high return on investment ensured by research efforts would benefit the industry. Contrarily, high costs associated with R&D capabilities, limited infrastructure, and insufficient research on the human microbiome are projected to stymie market expansion. In addition, a lack of favorable economic scenarios and technological penetration in emerging economies, obstacles to proving the causal connection between dysbiosis and illnesses, and a lack of suitable infrastructure in low & middle-income countries are expected to pose challenges to the market for the foreseeable future.
Human Microbiome Market Report Highlights
- North America will be the dominating region in the global market in 2021. The region’s dominance is attributed to factors such as the presence of well-established players and advancements in the R&D toward gut microbiome.
- By application, the therapeutics segment dominated the global market owing to increased funding for R&D into microbiome-based therapies across developing nations such as India and developed nations such as the US.
- By disease, infectious diseases account for the largest share owing to weak immune systems and less availability of nutritional diets across developing countries such as Africa, China, and India.
- By Product, the probiotic segment is the largest and fastest-growing segment owing to growing awareness among consumers for healthy and natural foods. Furthermore, the pandemic had a favorable impact on sales in this segment.
- Key players in the global market include Rebiotix., Metabiomics, Yakult Honsha, Osel Inc., Vedanta Biosciences, Synthetic Biologics, and DuPont.
Polaris Market Research has segmented the human microbiome market report based on type, application, disease, product, and region:
Human Microbiome, Product Outlook (Revenue – USD Million, 2018 – 2030)
- Medical Foods
Human Microbiome, Disease Outlook (Revenue – USD Million, 2018 – 2030)
Human Microbiome, Application Outlook (Revenue – USD Million, 2018 – 2030)
Human Microbiome, Type Outlook (Revenue – USD Million, 2018 – 2030)
- Live Biotherapeutic Product
Human Microbiome, Regional Outlook (Revenue – USD Million, 2018 – 2030)
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa